Pieter van Rompay
Fortuna: 4 M $ al 30/09/2026
Fortuna: 4 M $ al 30/09/2026
Pieter van Rompay has worked as a Director at EXO Biologics SA since 2019 and as a Managing Director & Director at Labo Phytophar NV since 2020.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products by reformulating well-known drugs 3,27 % | 31/03/2026 | 915.612 ( 3,27 % ) | 4 M $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
EXO Biologics SA
EXO Biologics SA BiotechnologyHealth Technology Operates as a biotechnology company | Director/Miembro de la Junta | 29/08/2019 |
Labo Phytophar NV
Labo Phytophar NV Food: Specialty/CandyConsumer Non-Durables Manufactures medicaments, condiments and seasonings | Director Ejecutivo | 30/10/2019 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 2 |
|---|---|
EXO Biologics SA
EXO Biologics SA BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Labo Phytophar NV
Labo Phytophar NV Food: Specialty/CandyConsumer Non-Durables Manufactures medicaments, condiments and seasonings | Consumer Non-Durables |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.